Publications:  Prof Peter Schmid

Verrill M, Wardley AM, Retzler J, Smith AB, Bottomley C, Ní Dhochartaigh S, Tran I, Leslie I et al.(2020). Health-related quality of life and work productivity in UK patients with HER2-positive breast cancer: a cross-sectional study evaluating the relationships between disease and treatment stage. Health and Quality of Life Outcomes vol. 18, (1)

Harder H, Shilling VM, May SF, Cella D, Schmid P, Fallowfield LJ(2020). The development and initial evaluation of the Diarrhoea Management Diary (DMD) in patients with metastatic breast cancer. Breast Cancer Research and Treatment vol. 183, (3) 629-638.

Robertson JFR, Evans A, Henschen S, Kirwan CC, Jahan A, Kenny LM, Dixon JM, Schmid P et al.(2020). A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER⁺ HER2^- Primary Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research vol. 26, (16) 4242-4249.

Huang M, O'Shaughnessy J, Zhao J, Haiderali A, Cortes J, Ramsey S, Briggsl A, Karantza V et al.(2020). Evaluation of pathologic complete response as a surrogate for long-term survival outcomes in triple-negative breast cancer. JNCCN Journal of the National Comprehensive Cancer Network vol. 18, (8) 1096-1104.

Schmid P, Dent R, O'Shaughnessy J(2020). Pembrolizumab for Early Triple-Negative Breast Cancer. Reply. The New England journal of medicine vol. 382, (26)

Adams S, Diéras V, Barrios CH, Winer EP, Schneeweiss A, Iwata H, Loi S, Patel S et al.(2020). Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer. Annals of Oncology vol. 31, (5) 582-589.

Schmid P, Salgado R, Park YH, Muñoz-Couselo E, Kim SB, Sohn J, Im SA, Foukakis T et al.(2020). Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study. Annals of Oncology vol. 31, (5) 569-581.

Schmid P, Cortes L, Pusztai L(2020). Pembrolizumab plus Neoadjuvant Chemotherapy Improves Pathologic Complete Response Rates in Triple-Negative Breast Cancer. Journal of Clinical Outcomes Management vol. 27, (2) 53-55.

Rugo HS, Bardia A, Tolaney SM, Arteaga C, Cortes J, Sohn J, Marmé F, Hong Q et al.(2020). TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2-metastatic breast cancer. Future Oncology vol. 16, (12) 705-712.

Cortes J, Perez-García JM, Llombart-Cussac A, Curigliano G, El Saghir NS, Cardoso F, Barrios CH, Wagle S et al.(2020). Enhancing global access to cancer medicines. CA Cancer Journal for Clinicians vol. 70, (2) 105-124.

Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH et al.(2020). Pembrolizumab for early triple-negative breast cancer. New England Journal of Medicine vol. 382, (9) 810-821.

Schmid P, Abraham J, Chan S, Wheatley D, Brunt AM, Nemsadze G, Baird RD, Park YH et al.(2020). Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: The PAKT trial. Journal of Clinical Oncology vol. 38, (5) 423-433.

Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Henschel V et al.(2020). Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology vol. 21, (1) 44-59.

Schmid P, Zaiss M, Harper-Wynne C, Ferreira M, Dubey S, Chan S, Makris A, Nemsadze G et al.(2019). Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women with Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial. JAMA Oncology vol. 5, (11) 1556-1563.

Cortés J, André F, Gonçalves A, Kümmel S, Martín M, Schmid P, Schuetz F, Swain SM et al.(2019). IMpassion132 Phase III trial: Atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer. Future Oncology vol. 15, (17) 1951-1961.

Rosenthal R, Cadieux EL, Salgado R, Bakir MA, Moore DA, Hiley CT, Lund T, Tani¿ M et al.(2019). Neoantigen-directed immune escape in lung cancer evolution. Nature vol. 567, (7749) 479-485.

Schmid P, Chui SY, Emens LA(2019). Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. Reply. The New England journal of medicine vol. 380, (10) 987-988.

Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, Cescon DW, Iwata H et al.(2019). Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: Cohort A of the phase II KEYNOTE-086 study. Annals of Oncology vol. 30, (3) 397-404.

Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M, Nanda R, Winer EP, Mukai H et al.(2019). Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: Cohort B of the phase II KEYNOTE-086 study. Annals of Oncology vol. 30, (3) 405-411.

Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, Tolaney SM, Kuter I, Nanda R et al.(2019). Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients with Metastatic Triple-Negative Breast Cancer: A Phase 1 Study. JAMA Oncology vol. 5, (1) 74-82.

Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Dieras V, Hegg R et al.(2018). Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. New England Journal of Medicine vol. 379, (22) 2108-2121.

Spigel DR, Chaft JE, Gettinger S, Chao BH, Dirix L, Schmid P, Chow LQM, Hicks RJ et al.(2018). FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1–Selected Patients With NSCLC. Journal of Thoracic Oncology vol. 13, (11) 1733-1742.

Kowanetz M, Zou W, Gettinger SN, Koeppen H, Kockx M, Schmid P, Kadel EE, Wistuba I et al.(2018). Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1). Proceedings of the National Academy of Sciences of the United States of America vol. 115, (43) E10119-E10126.

Schmid P(2018). ESMO 2018 presidential symposium - IMpassion130: Atezolizumab+nab-paclitaxel in triple-negative breast cancer. ESMO Open vol. 3, (6)

Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Dieras V, Hegg R et al.(2018). IMpassion130: Results from a global, randomised, double-blind, phase III study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC). Annals of oncology : official journal of the European Society for Medical Oncology vol. 29, viii707-viii708.

Chau I, Haag GM, Rahma OE, Macarulla TM, McCune SL, Yardley DA, Solomon BJ, Johnson M et al. (2018). MORPHEUS: A phase Ib/II umbrella study platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT)-based combinations in different tumour types. Annals of oncology : official journal of the European Society for Medical Oncology. vol. 29, viii439-viii440.

Winters ZE, Horsnell J, Elvers KT, Maxwell AJ, Jones LJ, Shaaban AM, Schmid P, Williams NR et al.(2018). Systematic review of the impact of breast-conserving surgery on cancer outcomes of multiple ipsilateral breast cancers. BJS Open vol. 2, (4) 162-174.

Schmid P, Cortes J, Bergh JCS, Pusztai L, Denkert C, Verma S, McArthur HL, Kummel S et al. (2018). KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant therapy followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC). Journal of Clinical Oncology. vol. 36, tps602-tps602.

Schmid PJ, Garciá-Gutierrez A, Jiménez J (2018). Description and detection of burst events in turbulent flows. Journal of Physics: Conference Series. vol. 1001,

Vargas FA, Furness AJS, Litchfield K, Joshi K, Rosenthal R, Ghorani E, Solomon I, Lesko MH et al.(2018). Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. Cancer Cell vol. 33, (4) 649-663.e4.

Roen A, Laut K, Pelchen-Matthews A, Borodulina E, Caldeira L, Clarke A, Clotet B, d'Arminio Monforte A et al.(2018). Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort. HIV Medicine vol. 19, (4) 252-260.

Garassino MC, Cho BC, Kim JH, Mazières J, Vansteenkiste J, Lena H, Corral Jaime J, Gray JE et al.(2018). Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. The Lancet Oncology vol. 19, (4) 521-536.

Fearon AE, Carter EP, Clayton NS, Wilkes EH, Baker AM, Kapitonova E, Bakhouche BA, Tanner Y et al.(2018). PHLDA1 Mediates Drug Resistance in Receptor Tyrosine Kinase-Driven Cancer. Cell Reports vol. 22, (9) 2469-2481.

Nathan MR, Schmid P(2018). The emerging world of breast cancer immunotherapy. Breast vol. 37, 200-206.

Shepherd L, Borges H, Harvey R, Bower M, Grulich A, Silverberg M, Weber J, Ristola M et al.(2018). The extent of B-cell activation and dysfunction preceding lymphoma development in HIV-positive people. HIV Medicine vol. 19, (2) 90-101.

Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O'Shaughnessy J, Gradishar W, Schmid P et al.(2018). Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer. Journal of Clinical Oncology vol. 36, (9) 884-890.

O'Leary K, Shia A, Schmid P(2017). Epigenetic Regulation of EMT in Non-Small Cell Lung Cancer. Curr Cancer Drug Targets vol. 18, (1) 89-96.

Cortés J, Im SA, Holgado E, Perez-Garcia JM, Schmid P, Chavez-MacGregor M(2017). The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies. Cancer Treatment Reviews vol. 61, 53-60.

McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, Birkbak NJ, Veeriah S et al.(2017). Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell vol. 171, (6) 1259-1271.e11.

De Laurentiis M, Montemurro F, Bachelot T, Martin M, Barrios C, Kaufman B, Schmid P, Alba E et al.(2017). The role of ribociclib in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer: the EarLEE adjuvant clinical trials program. Annals of oncology : official journal of the European Society for Medical Oncology vol. 28,

Schmid P, Blackhall F, Muthukumar D, Lester J, Khan S, Adams J, Illsley M, Macgregor C et al. (2017). A phase II, randomised, open-label study of gemcitabine/carboplatin first-line chemotherapy in combination with or without the antisense oligonucleotide apatorsen (OGX-427) in advanced squamous cell lung cancers. ANNALS OF ONCOLOGY. Conference: ESMO vol. 28,

Schulz C, Schmid P, Hedge P, Zou W, Kowanetz M, Mariathasan S, Gadgeel S, Powles T et al. (2017). Association of PD-L2 expression in human tumors with atezolizumab activity. ONCOLOGY RESEARCH AND TREATMENT. vol. 40, 134-134.

Martin Jimenez M, Bachelot T, Barrios C, Blackwell K, Chia S, De Laurentiis M, Hurvitz S, Janni W et al. (2017). EarLEE-1: A phase 3 study of ribociclib plus endocrine therapy (ET) for adjuvant treatment of patients (pts) with hormone receptor-positive (HR1), human epidermal growth factor receptor 2-negative (HER2-), high-risk, early breast cancer (EBC). ANNALS OF ONCOLOGY. vol. 28,

Loi S, Adams S, Schmid P, Cortes J, Cescon DW, Winer EP, Toppmeyer DL, Rugo HS et al. (2017). Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086. ANNALS OF ONCOLOGY. vol. 28,

Beddowes E, Spicer J, Chan PY, Khadeir R, Garcia Corbacho J, Repana D, Steele JP, Schmid P et al.(2017). Phase 1 dose-escalation study of pegylated arginine deiminase, cisplatin, and pemetrexed in patients with argininosuccinate synthetase 1–deficient thoracic cancers. Journal of Clinical Oncology vol. 35, (16) 1778-1785.

Schmid P, Forster MD, Summers YJ, Good J, Sarker S-J, Lim L, Mousa K, Middleton GW (2017). A study of vistusertib in combination with selumetinib in patients with advanced cancers: TORCMEK phase Ib results. JOURNAL OF CLINICAL ONCOLOGY. Conference: ESMO vol. 35,

Borges ÁH, Hoy J, Florence E, Sedlacek D, Stellbrink HJ, Uzdaviniene V, Tomazic J, Gargalianos-Kakolyris P et al.(2017). Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort. Clinical Infectious Diseases vol. 64, (10) 1413-1421.

Seckl MJ, Ottensmeier CH, Cullen M, Schmid P, Ngai Y, Muthukumar D, Thompson J, Harden S et al.(2017). Multicenter, phase III, randomized, double-blind, placebo-controlled trial of pravastatin added to first-line standard chemotherapy in small-cell lung cancer (LUNGSTAR). Journal of Clinical Oncology vol. 35, (14) 1506-1514.

Oke A, Knox J, Tan J, Aigret B, Schmid P, Coleman RE, Cuzick J, Thorat MA (2017). Barriers to recruitment from primary care into a trial in secondary care settings: experience from the feasibility study of IBIS-3 trial. TRIALS. Conference: ICTMC/SCT 2017 vol. 18,

Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA et al.(2017). Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature vol. 545, (7655) 446-451.

Arce Vargas F, Furness AJS, Solomon I, Joshi K, Mekkaoui L, Lesko MH, Miranda Rota E, Dahan R et al.(2017). Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. Immunity vol. 46, (4) 577-586.

López-Miranda E, Gávila J, Pernas S, Saura C, Oliveira M, Serra V, Schmid P, Lord S et al. (2017). Abstract OT1-01-06: PIQHASSO: Open label, non-randomized, multicenter phase 1/2b study investigating safety and efficacy of PQR309 and eribulin combination in patients (pts) with locally advanced (LA) or metastatic HER2 (-) and triple-negative breast cancer (TNBC) (study PQR309-007).

Lenihan C, Bouchekioua-Bouzaghou K, Abdulghani R, Chupin J, Shia A, Schmid P (2017). Abstract P3-03-12: CDK4/6 inhibitor resistant ER-positive cells remain dependent on estrogen signalling and retain sensitivity to endocrine therapy.

Schmid P, Pinder SE, Purushotham A, Thompson AM(2017). Reply to R.F. Sweis et al. Journal of Clinical Oncology vol. 35, (2) 261-262.

Szlosarek PW, Steele JP, Nolan L, Gilligan D, Taylor P, Spicer J, Lind M, Mitra S et al.(2017). Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial. JAMA oncology vol. 3, (1) 58-66.

Szlosarek PW, Steele JP, Nolan L, Gilligan D, Taylor P, Spicer J, Lind M, Mitra S et al.(2017). Arginine deprivation with pegylated arginine deiminase in patients with argininosuccinate synthetase 1-deficient malignant pleural mesothelioma a randomized clinical trial. JAMA Oncology vol. 3, (1) E1-E9.

Hentrich M, Schipek-Voigt K, Jäger H, Schulz S, Schmid P, Stötzer O, Bojko P(2017). Nivolumab in HIV-related non-small-cell lung cancer. Annals of Oncology vol. 28, (11)

Jehn CF, Hemmati P, Lehenbauer-Dehm S, Kümmel S, Flath B, Schmid P(2016). Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study. Clinical Breast Cancer vol. 16, (6) 514-519.

Mok T, Schmid P, Jr DCG, Syrigos K, Martin C, Yamamoto N, Aren O, Arrieta O et al. (2016). Global, Phase 3 study of first-line durvalumab (MEDI4736) + tremelimumab vs standard of care platinum-based chemotherapy in advanced/metastatic NSCLC: NEPTUNE. ANNALS OF ONCOLOGY. vol. 27,

Emens L, Adams S, Loi S, Schneeweiss A, Rugo H, Winer E, Barrios C, Dieras V et al. (2016). IMpassion130: Phase III trial comparing 1L atezolizumab with nab-paclitaxel versus placebo with nab-paclitaxel in treatment-naive patients with mTNBC. ANNALS OF ONCOLOGY. vol. 27,

Ma BBY, Rudin CM, Cervantes A, Dowlati A, Costa D, Schmid P, Heist R, Villaflor VM et al. (2016). Preliminary safety and clinical activity of erlotinib plus atezolizumab from a Phase Ib study in advanced NSCLC. ANNALS OF ONCOLOGY. vol. 27,

Schmid P, Melisko M, Yardley DA, Blackwell K, Forero A, Ouellette G, He Y, Bagley RG et al. (2016). METRIC: A randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC). Annals of Oncology. vol. 27,

Spoerke JM, Gendreau S, Walter K, Qiu J, Wilson TR, Savage H, Aimi J, Derynck MK et al.(2016). Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant. Nature Communications vol. 7, (1)

Lenihan C, Cavicchioli F, O¿Leary K, Shia A, Schmid P (2016). Abstract 2110: The role of VAV-interacting Kruppel-like factor (VIK) in resistance to palbociclib in estrogen receptor-positive breast cancer. 2110-2110.

Bouchekioua-Bouzaghou K, Lenihan C, Shia A, Wilkes E, Casado-Izquierdo P, Cutillas P, Schmid P (2016). Abstract 2819: Characterization of the mechanisms of early and later stages of resistance to the selective CDK4/6 inhibitor palbociclib. 2819-2819.

Komulainen E, Shia A, Bansal J, Cavicchioli F, O¿Leary K, Foster J, Schmid P (2016). Abstract 3759: Inhibition of heat shock protein 27 (Hsp27) expression by apatorsen as a therapeutic strategy in breast cancer. 3759-3759.

Schmid P, Pinder SE, Wheatley D, Macaskill J, Zammit C, Hu J, Price R, Bundred N et al.(2016). Phase II randomized preoperative window-of-opportunity study of the PI3K inhibitor pictilisib plus anastrozole compared with anastrozole alone in patients with estrogen receptor-positive breast cancer. Journal of Clinical Oncology vol. 34, (17) 1987-1994.

Krop IE, Mayer IA, Ganju V, Dickler M, Johnston S, Morales S, Yardley DA, Melichar B et al.(2016). Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Oncology vol. 17, (6) 811-821.

Schmid P, Wheatley DA, Thompson AM, Roy P, Bundred NJ, Purushotham AD, McIntosh S, Kummel S et al. (2016). ARB: Phase II window of opportunity study of short-term preoperative treatment with enzalutamide in ER-positive and triple-negative breast cancer. JOURNAL OF CLINICAL ONCOLOGY. Conference: ASCO vol. 34,

Mok T, Schmid P, Arén O, Arrieta O, Gottfried M, Jazieh AR, Ramlau R, Timcheva K et al.(2016). 192TiP: NEPTUNE: A global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy versus standard of care (SoC) platinum-based chemotherapy in the first-line treatment of patients (pts) with advanced or metastatic NSCLC. Journal of Thoracic Oncology vol. 11, (4) S140-S141.

Cortes J, Martinez Janesz N, Sablin MP, Perez-Fidalgo JA, Neven P, Hedayati E, Ballester A, Ehrhart MP et al. (2016). Phase 1b/2 trial of BI 836845, an insulin-like growth factor (IGF) ligand-neutralising antibody, in combination with exemestane and everolimus in postmenopausal women with hormone receptor-positive, locally advanced or metastatic breast cancer: Preliminary results of the Phase 1b part. EUROPEAN JOURNAL OF CANCER. vol. 57, S112-S112.

Winters ZE, Horsnell J, Schmid P, Jones JL, Shaaban A, Maxwell AJ, Williams N, Esserman L et al.(2016). Time for a randomised clinical trial evaluating breast conserving surgery compared to mastectomy in ipsilateral mutlifocal breast cancer (MFBC)?. Breast vol. 26, 149-150.

Emens L, Adams S, Loi S, Schmid P, Schneeweiss A, Rugo H, Chui S, Winer E (2016). Abstract OT1-01-06: A phase III randomized trial of atezolizumab in combination with nab-paclitaxel as first line therapy for patients with metastatic triple-negative breast cancer (mTNBC).

Schmid P, Ferreira M, Dubey S, Zaiss M, Harper-Wynne C, Makris A, Brown V, Kristeleit H et al. (2016). Abstract OT1-03-12: MANTA: A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer.

Schmid P, Wheatley D, Baird R, Chan S, Abraham J, Tutt A, Kristeleit H, Patel G et al. (2016). Abstract OT1-03-13: A phase II, double blind, randomised, placebo-controlled study of the AKT Inhibitor AZD5363 in combination with paclitaxel in triple-negative advanced or metastatic breast cancer (TNBC)(NCT02423603).

Lenihan C, Bouchekioua-Bouzaghou K, Shia A, Wilkes E, Casado-Izquierdo P, Cutillas P, Schmid P (2016). Abstract P3-06-02: Characterization of resistance to the selective CDK4/6 inhibitor palbociclib in ER positive breast cancer.

Hampsch R, Shee K, Miller T (2016). Abstract P5-03-01: Therapeutic targeting of Rac GTPases in ER+ and HER2+ breast cancer.

Schmid P, Pinder S, Bundred N, Wheatley D, Macaskill J, Zammit C, Hu J, Price R et al. (2016). Abstract P5-13-01: Transcript analysis of PI3K and immune-related genes and gene signatures in the pre- and post-treatment samples from the window of opportunity study of anastrozole and anastrozole with pictilisib (GDC-0941) in patients with HR-positive early breast cancer (OPPORTUNE study).

Spoerke J, Gendreau S, Johnston S, Schmid P, Krop I, Qui J, Derynck M, Chan I et al. (2016). Abstract PD6-03: High prevalence and clonal heterogeneity of ESR1 mutations (mt) in circulating tumor DNA (ctDNA) from patients (pts) enrolled in FERGI, a randomized phase II study testing pictilisib (GDC-0941) in combination with fulvestrant (F) in pts that failed a prior aromatase inhibitor (AI).

Spoerke J, Gendreau S, Johnston S, Schmid P, Krop I, Qui J, Derynck M, Chan I et al. (2016). High prevalence and clonal heterogeneity of ESR1 mutations (mt) in circulating tumor DNA (ctDNA) from patients (pts) enrolled in FERGI, a randomized phase II study testing pictilisib (GDC-0941) in combination with fulvestrant (F) in pts that failed a prior aromatase inhibitor (AI). CANCER RESEARCH. vol. 76,

Mok T, Schmid P, Aren O, Arrieta O, Gottfried M, Jazieh AR, Ramlau R, Timcheva C et al. (2015). Phase 3, randomised, open-label study of durvalumab (MEDI4736) in combination with tremelimumab versus platinum-based chemotherapy in first-line treatment of patients with advanced or metastatic NSCLC: NEPTUNE. ANNALS OF ONCOLOGY. vol. 26, 147-147.

Schmid P, Kowanetz M, Koeppen H, Zou W, Wistuba I, Kockx M, Kadel EE, Chaft J et al. (2015). 3017 NSCLC with high PD-L1 expression on tumor cells or tumorinfiltrating immune cells represents distinct cancer subtypes. European Journal of Cancer. vol. 51,

Schmid P, Muthukumar D, Blackhall F, Lester J, Khan S, Illsley MC, Adams J, Baijal S et al.(2015). Addition of Hsp27 Inhibitor Apatorsen to First-Line Gemcitabine/Carboplatin in Advanced Squamous Cell Lung Cancer: Design of the Cedar (TM) Trial. JOURNAL OF THORACIC ONCOLOGY vol. 10, (9) S664-S664.

O Leary K, Shia A, Cavicchioli F, Haley V, Comino A, Merlano M, Mauri F, Walter K et al.(2015). Identification of Endoglin as an epigenetically regulated tumour-suppressor gene in lung cancer. British Journal of Cancer

Diéras V, Campone M, Yardley DA, Romieu G, Valero V, Isakoff SJ, Koeppen H, Wilson TR et al.(2015). Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer. Annals of Oncology vol. 26, (9) 1904-1910.

Schmid P, Muthukumar D, Blackhall FH, Lester JF, Khan S, Illsley M, Adams J, Garcia-Alonso A et al. (2015). Addition of apatorsen, an inhibitor of Hsp27, to first-line gemcitabine/carboplatin in advanced squamous cell lung cancer: Design of the Cedar study. JOURNAL OF CLINICAL ONCOLOGY. vol. 33,

Spigel DR, Chaft JE, Gettinger SN, Chao BH, Dirix LY, Schmid P, Chow LQM, Chappey C et al. (2015). Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1-selected patients with non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY. vol. 33,

Szlosarek PW, Spicer JF, Szyszko T, Cook GJR, Chan PY, Hategan M, Repana D, Steele JP et al. (2015). Phase I study of ADI-PEG 20 in combination with pemetrexed and cisplatin (TRAP) in patients with ASS1-deficient mesothelioma and non-squamous lung cancer. Journal of Clinical Oncology. vol. 33, tps2612-tps2612.

Krop I, Johnston S, Mayer IA, Dickler M, Ganju V, Forero-Torres A, Melichar B, Morales S et al. (2015). Abstract S2-02: The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER+, aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer – Part I results.

Schmid P, Pinder SE, Wheatley D, Macaskill J, Zammit C, Hu J, Price R, Bundred N et al. (2015). Abstract S2-03: Preoperative window of opportunity study of the PI3K inhibitor pictilisib (GDC-0941) plus anastrozole vs anastrozole alone in patients with ER+, HER2-negative operable breast cancer (OPPORTUNE study).

Cortes Castan J, Schmid P, Awada A, Uppal H, Tudor IC, Blaney ME, Steinberg JL, Yardley DA et al. (2015). Stage 1 results from MDV3100-11: A 2-stage study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR plus triple-negative breast cancer (TNBC). ANNALS OF ONCOLOGY. vol. 26,

Cortes Castan J, Schmid P, Awada A, Uppal H, Tudor IC, Blaney ME, Steinberg JL, Yardley DA et al.(2015). Stage 1 results from MDV3100-11: A 2-stage study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC). Annals of Oncology vol. 26,

O'Leary K, Shia A, Cavicchioli F, Haley V, Comino A, Merlano M, Mauri F, Walter K et al.(2015). Identification of Endoglin as an epigenetically regulated tumour-suppressor gene in lung cancer. British Journal of Cancer vol. 113, (6) 970-978.

Jehn CF, Becker B, Flath B, Nogai H, Vuong L, Schmid P, Lüftner D(2015). Neurocognitive function, brain-derived neurotrophic factor (BDNF) and IL-6 levels in cancer patients with depression. Journal of Neuroimmunology vol. 287, 88-92.

Neumayr G, Fries D, Mittermayer M, Humpeler E, Klingler A, Schobersberger W, Spiesberger R, Pokan R et al.(2014). Effects of hiking at moderate and low altitude on cardiovascular parameters in male patients with metabolic syndrome: Austrian Moderate Altitude Study. Wilderness & environmental medicine vol. 25, (3) 329-334.

Meisenberg C, Ward SE, Schmid P, El-Khamisy SF(2014). TDP1/TOP1 Ratio as a Promising Indicator for the Response of Small Cell Lung Cancer to Topotecan. J Cancer Sci Ther vol. 6, (7) 258-267.

Cope S, Zhang J, Saletan S, Smiechowski B, Jansen JP, Schmid P(2014). A process for assessing the feasibility of a network meta-analysis: A case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer. BMC Medicine vol. 12, (1)

Dizdarevic S, McCready R, Turner JFC, Bagley MC, Blower P, Schmid P, Flux G, Hall A et al.(2014). Radiolabelled apoptotic probe may be a vehicle for a novel multimodality radionuclide tumour therapy. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING vol. 41, (6) 1255-1256.

Traina TA, O'Shaughnessy J, Kelly CM, Schwartzberg LS, Gucalp A, Peterson AC, Tudor IC, Blaney ME et al. (2014). A phase 2 single-arm study of the clinical activity and safety of enzalutamide in patients with advanced androgen receptor-positive triple-negative breast cancer. Journal of Clinical Oncology. vol. 32, tps1144-tps1144.

Britton D, Zen Y, Quaglia A, Selzer S, Mitra V, Löbner C, Jung S, Böhm G et al.(2014). Quantification of pancreatic cancer proteome and phosphorylome: Indicates molecular events likely contributing to cancer and activity of drug targets. PLoS ONE vol. 9, (3)

Besse B, Heist RS, Papadmitrakopoulou VA, Camidge DR, Beck JT, Schmid P, Mulatero C, Miller N et al.(2014). A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer. ANNALS OF ONCOLOGY vol. 25, (2) 505-511.

Wonisch M, Berent R, Klicpera M, Laimer H, Marko C, Pokan R, Schmid P, Schwann H(2014). Practice guidelines for exercise testing. Atemwegs- und Lungenkrankheiten vol. 40, (6) 223-244.

Denne L, Shia A, Komulainen E, Haley V, Lenihan C, Cavicchioli F, O'Leary K, Schmid P(2013). Abstract P2-09-05: The potent anti-androgen enzalutamide demonstrates broad anti-tumour activity across all androgen receptor-positive triple-negative breast cancer subtypes.

Eccles SA, Aboagye EO, Ali S, Anderson AS, Armes J, Berditchevski F, Blaydes JP, Brennan K et al.(2013). Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Research vol. 15, (5)

Cavicchioli F, Shia A, O'Leary K, Haley V, Crook T, Thompson AM, Lackner M, Jones LJ et al. (2013). Sensitivity to glutamine deprivation is dependent on the interplay between epigenetic regulation of Glutamine synthetase (Glul) and induction of autophagy. EUROPEAN JOURNAL OF CANCER. vol. 49, S141-S141.

Coombes RC, Cardoso F, Isambert N, Lesimple T, Soulié P, Peraire C, Fohanno V, Kornowski A et al.(2013). A phase i dose escalation study to determine the optimal biological dose of irosustat, an oral steroid sulfatase inhibitor, in postmenopausal women with estrogen receptor-positive breast cancer. Breast Cancer Research and Treatment vol. 140, (1) 73-82.

Cope S, Ouwens MJNM, Jansen JP, Schmid P(2013). Progression-free survival with fulvestrant 500 mg and alternative endocrine therapies as second-line treatment for advanced breast cancer: A network meta-analysis with parametric survival models. Value in Health vol. 16, (2) 403-417.

Eder B, Hofmann P, Hödl R, Wonisch M, Schmid P, Pokan R(2013). Cardiac rehabilitation effective in elderly patients?. Journal fur Kardiologie vol. 20, (9-10) 262-268.

Aad G, Abajyan T, Abbott B, Abdallah J, Khalek SA, Abdelalim AA, Abdinov O, Aben R et al.(2012). A Particle Consistent with the Higgs Boson Observed with the ATLAS Detector at the Large Hadron Collider. SCIENCE vol. 338, (6114) 1576-1582.

Cavicchioli F, Shia A, O'Leary K, Haley V, Crook T, Thompson A, Lackner M, Lo NC et al. (2012). Abstract P4-06-10: Epigenetic silencing of glutamine synthetase (Glul) defines glutamine depletion therapy.

Zappa F, Droege C, Betticher D, von Moos R, Bubendorf L, Ochsenbein A, Gautschi O, Oppliger Leibundgut E et al.(2012). Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05). Lung Cancer vol. 78, (3) 239-244.

Hatzimichael E, Lo Nigro C, Lattanzio L, Syed N, Shah R, Dasoula A, Janczar K, Vivenza D et al.(2012). The collagen prolyl hydroxylases are novel transcriptionally silenced genes in lymphoma. British Journal of Cancer vol. 107, (8) 1423-1432.

Aad G, Abajyan T, Abbott B, Abdallah J, Abdel Khalek S, Abdelalim AA, Abdinov O, Aben R et al.(2012). Observation of a new particle in the search for the Standard Model Higgs boson with the ATLAS detector at the LHC. Physics Letters, Section B: Nuclear, Elementary Particle and High-Energy Physics vol. 716, (1) 1-29.

Cavicchioli F, Shia A, O'Leary K, Haley V, Palmieri C, Syed N, Crook T, Thompson AM et al. (2012). EPIGENETIC SILENCING OF ARGININO-SUCCINATE SYNTHASE (ASS1) DEFINES ARGININE DEPLETION THERAPY AS A NOVEL TREATMENT STRATEGY FOR BREAST CANCER. ANNALS OF ONCOLOGY. vol. 23, 532-533.

O'Leary K, Shia A, Haley V, Cavicchioli F, Comino A, Vanella P, Wischnewsky M, Crook T et al. (2012). IDENTIFICATION OF ENDOGLIN (CD105) AS AN EPIGENETICALLY REGULATED CANDIDATE TUMOUR SUPPRESSOR GENE IN LUNG CANCER. ANNALS OF ONCOLOGY. vol. 23, 73-74.

Wonisch M, Marko C, Niebauer J, Pokan R, Schmid P, Wiesinger E(2012). Resistance training for patients with cardiovascular diseases. Wiener Klinische Wochenschrift vol. 124, (9-10) 326-333.

Berent R, Von Duvillard SP, Crouse SF, Auer J, Green JS, Niebauer J, Sinzinger H, Schmid P(2012). Discontinuation of combined resistance-endurance training increases cardiovascular risk factors. International Journal of Cardiology vol. 156, (2) 229-231.

Blohmer JU, Paepke S, Sehouli J, Boehmer D, Kolben M, Wur¿schmidt F, Petry KU, Kimmig R et al.(2011). Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin alfa in patients with high-risk cervical cancer: Results of the NOGGO-AGO intergroup study. Journal of Clinical Oncology vol. 29, (28) 3791-3797.

Berent R, Von Duvillard SP, Crouse SF, Sinzinger H, Green JS, Schmid P(2011). Resistance training dose response in combined endurance-resistance training in patients with cardiovascular disease: A randomized trial. Archives of Physical Medicine and Rehabilitation vol. 92, (10) 1527-1533.

Berent R, Auer J, Franklin B, Schmid P, Von Duvillard SP(2011). Platelet response to aspirin 50 and 100 mg in patients with coronary heart disease over a five-year period. American Journal of Cardiology vol. 108, (5) 644-650.

Abe O, Abe R, Enomoto K, Kikuchi K, Koyama H, Masuda H, Nomura Y, Ohashi Y et al.(2011). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. The Lancet vol. 378, (9793) 771-784.

Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Smith DA, Yancey LJ, Crump M et al.(2011). High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: Overview of six randomized trials. Journal of Clinical Oncology vol. 29, (24) 3224-3231.

Eggeman H, Stöblen F, Thill M, Korlach S, Schmid P, Lüftner D, Elling D, Taran FA et al.(2011). Influence of a dose-dense adjuvant chemotherapy on sVCAM-1/sICAM-1 serum levels in breast cancer patients with 1-3 positive lymph nodes. Anticancer Research vol. 31, (8) 2617-2622.

Landt S, Wehling M, Heidecke H, Jeschke S, Korlach S, Stoblen F, Schmid P, Blohmer JU et al.(2011). Prognostic significance of angiogenic factors in uterine cervical cancer. Anticancer Research vol. 31, (8) 2589-2595.

Syed N, Coley HM, Sehouli J, Koensgen D, Mustea A, Szlosarek P, McNeish I, Blagden SP et al.(2011). Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer. Cancer Res vol. 71, (9) 3317-3327.

White S, Harvey R, Mitchell H, Schmid P, Seckl M, Savage P(2011). Characterisation of transient benign hCG elevations in women following chemotherapy for GTT. Journal of Obstetrics and Gynaecology vol. 31, (2) 169-172.

SCHMID-ARAYA J, Figueroa Hernandez D, Schmid PE, Drouot C(2011). Algivory in food webs of three temperate Andean rivers. Austral Ecology

Berent R, Auer J, Schmid P, Krennmair G, Crouse SF, Green JS, Sinzinger H, Von Duvillard SP(2011). Periodontal and coronary heart disease in patients undergoing coronary angiography. Metabolism: Clinical and Experimental vol. 60, (1) 127-133.

Huber K, Saely CH, Drexel H, Francesconi M, Gaul G, Glehr R, Lang IM, Marko C et al.(2011). Practical implementation of guidelines for lipid lowering. Journal fur Kardiologie vol. 18, (3-4) 96-99.

Aad G, Abbott B, Abdallah J, Abdelalim AA, Abdesselam A, Abdinov O, Abi B, Abolins M et al.(2010). Drift Time Measurement in the ATLAS Liquid Argon Electromagnetic Calorimeter using Cosmic Muons. EUR PHYS J C vol. 70, (3) 755-785.

Aad G, Abbott B, Abdallah J, Abdelalim AA, Abdesselam A, Abdinov O, Abi B, Abolins M et al.(2010). Readiness of the ATLAS liquid argon calorimeter for LHC collisions. EUR PHYS J C vol. 70, (3) 723-753.

Jehn CF, Kühnhardt D, Bartholomae A, Pfeiffer S, Schmid P, Possinger K, Flath BC, Lüftner D(2010). Association of IL-6, hypothalamus-pituitary-adrenal axis function, and depression in patients with cancer. Integrative Cancer Therapies vol. 9, (3) 270-275.

Oguogho A, Efthimiou Y, Iliopoulos J, Stomatopoulos J, Ahmadzadehfar H, Schmid P, Steinbrenner D, Sinzinger H(2010). Prickly pear changes ¹¹¹indium?LDL and ¹¹¹indium-HDL platelet binding correlating to improvement of platelet function in hypercholesterolemia. Journal of the Professional Association for Cactus Development vol. 12, 67-79.

Blackhall FH, Obrien M, Schmid P, Nicolson M, Taylor P, Milenkova T, Kennedy SJ, Thatcher N(2010). A phase i study of vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer. Journal of Thoracic Oncology vol. 5, (8) 1285-1288.

Berent R, Auer J, Von Duvillard SP, Sinzinger H, Schmid P(2010). Complications during exercise testing. Herz vol. 35, (4) 267-272.

Schmid PE, Schmid-Araya JM(2010). Scale-dependent relations between bacteria, organic matter and invertebrates in a headwater stream. FUND APPL LIMNOL vol. 176, (4) 365-375.

McGrath S, Short D, Harvey R, Schmid P, Savage PM, Seckl MJ(2010). The management and outcome of women with post-hydatidiform mole low-risk gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU l^-1. British Journal of Cancer vol. 102, (5) 810-814.

Blohmer JU, Schmid P, Hilfrich J, Friese K, Kleine-Tebbe A, Koelbl H, Sommer H, Morack G et al.(2010). Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer: Final results of a randomised phase III trial. Annals of Oncology vol. 21, (7) 1430-1435.

Berent R, Auer J, Von Duvillard S, Sinzinger H, Steinbrenner D, Schmid P(2010). Acute myocardial infarction with ST segment elevation in inferior and anterior leads: Right ventricular infarction. BMJ Case Reports

Berent R, von Duvillard SP, Auer J, Sinzinger H, Schmid P(2010). Lack of supervision after residential cardiac rehabilitation increases cardiovascular risk factors. European Journal of Preventive Cardiology vol. 17, (3) 296-302.

Davidson N, Gelber R, Piccart M, Pruneri G, Pritchard K, Ravdin P, Robertson J, Swain S et al.(2010). Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. Journal of the National Cancer Institute - Monographs vol. 41, 162-177.

Beslija S, Bonneterre J, Burstein HJ, Cocquyt V, Gnant M, Heinemann V, Jassem J, Köstler WJ et al.(2009). Third consensus on medical treatment of metastatic breast cancer. Annals of Oncology vol. 20, (11) 1771-1785.

Schmid P, Kiewe P, Possinger K, Korfel A, Lindemann S, Giurescu M, Reif S, Wiesinger H et al.(2009). Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors. Annals of Oncology vol. 21, (3) 633-639.

Nicholson LJ, Smith PR, Hiller L, Szlosarek PW, Kimberley C, Sehouli J, Koensgen D, Mustea A et al.(2009). Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer. Int J Cancer vol. 125, (6) 1454-1463.

Schmid P, Nagai Y, Agarwal R, Hancock B, Savage PM, Sebire NJ, Lindsay I, Wells M et al.(2009). Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study. The Lancet vol. 374, (9683) 48-55.

Schmid P, Krocker J, Kreienberg R, Klare P, Kittel K, Sommer H, Heinrich G, Steck T et al.(2009). Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: Final results of a phase II trial. Cancer Chemotherapy and Pharmacology vol. 64, (2) 401-406.

Kuemmel S, Thomas A, Landt S, Fuger A, Schmid P, Kriner M, Blohmer JU, Sehouli J et al.(2009). Circulating vascular endothelial growth factors and their soluble receptors in pre-invasive, invasive and recurrent cervical cancer. Anticancer Research vol. 29, (2) 641-645.

Berent R, Von Duvillard SP, Crouse SF, Auer J, Green JS, Sinzinger H, Schmid P(2009). Short-term residential cardiac rehabilitation reduces B-type natriuretic peptide. European Journal of Cardiovascular Prevention and Rehabilitation vol. 16, (5) 603-608.

Wonisch M, Berent R, Klicpera M, Laimer H, Marko C, Pokan R, Schmid P, Schwann H(2008). Practice guidelines for exercise testing. Journal fur Kardiologie vol. 15, (SUPPL. A) 3-17.

Wang J, Short D, Sebire NJ, Lindsay I, Newlands ES, Schmid P, Savage PM, Seckl MJ(2008). Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/ etoposide (TP/TE). Annals of Oncology vol. 19, (9) 1578-1583.

Harvey RA, Pursglove HD, Schmid P, Savage PM, Mitchell HDC, Seckl MJ(2008). Human chorionic gonadotropin free β-subunit measurement as a marker of placental site trophoblastic tumors. Journal of Reproductive Medicine for the Obstetrician and Gynecologist vol. 53, (8) 643-648.

Lim AKP, Patel D, Patel N, Hawtin K, Dayal L, Schmid P, Savage P, Seckl MJ(2008). Pelvic imaging in gestational trophoblastic neoplasia. Journal of Reproductive Medicine for the Obstetrician and Gynecologist vol. 53, (8) 575-578.

Aad G, Abat E, Abdallah J, Abdelalim AA, Abdesselam A, Abdinov O, Abi BA, Abolins M et al.(2008). The ATLAS Experiment at the CERN Large Hadron Collider. J INSTRUM vol. 3, Article S08003,

Schmid P, Kühnhardt D, Kiewe P, Lehenbauer-Dehm S, Schippinger W, Greil R, Lange W, Preiss J et al.(2008). A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. Annals of Oncology vol. 19, (5) 871-876.

Fürstenberger G, Schmid P, Duquesne A, Ammann M, Senn HJ(2008). Complete remission of a metastatic neuroendocrine tumor of the pancreas with capecitabine (Xeloda®) monotherapy. Cancer Chemotherapy and Pharmacology vol. 61, (2) 347-348.

Schmid P(2007). Bisphosphonate for the treatment of tumor induced in bone changes. Onkologe vol. 13, (7) 609-618.

Colleoni M, Gelber S, Simoncini E, Pagani O, Gelber RD, Price KN, Castiglione-Gertsch M, Coates AS et al.(2007). Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: Results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93. Annals of Oncology vol. 18, (7) 1177-1184.

Schmid P, Untch M, Kossé V, Bondar G, Vassiljev L, Tarutinov V, Lehmann U, Maubach L et al.(2007). Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: The TABLE study. Journal of Clinical Oncology vol. 25, (18) 2509-2515.

Schmid P(2007). High-dose chemotherapy for breast cancer. Onkologe vol. 13, (5) 409-424.

Powles T, Savage PM, Stebbing J, Short D, Young A, Bower M, Pappin C, Schmid P et al.(2007). A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia. British Journal of Cancer vol. 96, (5) 732-737.

Kümmel S, Rezai M, Kimmig R, Schmid P(2007). Dose-dense chemotherapy for primary breast cancer. Current Opinion in Obstetrics and Gynecology vol. 19, (1) 75-81.

Beslija S, Bonneterre J, Burstein H, Cocquyt V, Gnant M, Goodwin P, Heinemann V, Jassem J et al.(2007). Second consensus on medical treatment of metastatic breast cancer. Annals of Oncology vol. 18, (2) 215-225.

Kümmel S, Eggemann H, Lüftner D, Gebauer N, Bühler H, Schaller G, Schmid P, Kreienberg R et al.(2007). Significant changes in circulating plasma levels of IGF1 and IGFBP3 after conventional or dose-intensified adjuvant treatment of breast cancer patients with one to three positive lymph nodes. International Journal of Biological Markers vol. 22, (3) 186-193.

Powles T, Young A, Sanitt A, Stebbing J, Short D, Bower M, Savage PM, Seckl MJ et al.(2006). Erratum: The significance of the time interval between antecedent pregnancy and diagnosis of high-risk gestational trophoblastic tumours (British Journal of Cancer (2006) 95, (1145-1147) DOI: 10.1038/sj.bjc.6603416). British Journal of Cancer vol. 95, (12)

Jehn CF, Kuehnhardt D, Bartholomae A, Pfeiffer S, Krebs M, Regierer AC, Schmid P, Possinger K et al.(2006). Biomarkers of depression in cancer patients. Cancer vol. 107, (11) 2723-2729.

Possinger K, Schmid P(2006). Chemotherapy for metastatic breast cancer. Zentralblatt fur Gynakologie vol. 128, (6) 318-326.

Schmid P(2006). Mechanism of action and application possibilities: Adjuvant hormonal therapy of breast carcinoma. Best Practice Onkologie vol. 1, (1) 42-57.

Powles T, Young A, Sammit A, Stebbing J, Short D, Bower M, Savage PM, Seckl MJ et al.(2006). The significance of the time interval between antecedent pregnancy and diagnosis of high-risk gestational trophoblastic tumours. British Journal of Cancer vol. 95, (9) 1145-1147.

Dhillon T, Palmieri C, Sebire NJ, Lindsay I, Newlands ES, Schmid P, Savage PM, Frank J et al. (2006). Value of whole body ¹⁸FDG-PET to identify the active site of gestational trophoblastic neoplasia. Journal of Reproductive Medicine for the Obstetrician and Gynecologist. vol. 51, 879-887.

Murugaesu N, Schmid P, Dancey G, Agarwal R, Holden L, McNeish I, Savage PM, Newlands ES et al.(2006). Malignant ovarian germ cell tumors: Identification of novel prognostic markers and long-term outcome after multimodality treatment. Journal of Clinical Oncology vol. 24, (30) 4862-4866.

Pokan R, Hofmann P, Von Duvillard SP, Smekal G, Wonisch M, Lettner K, Schmid P, Shechter M et al.(2006). Oral magnesium therapy, exercise heart rate, exercise tolerance, and myocardial function in coronary artery disease patients. British Journal of Sports Medicine vol. 40, (9) 773-778.

Powles T, Young A, Short D, Savage P, Pappin C, Schmid P, Seckl M(2006). The outcome of patients with relapsed gestational trophoblastic neoplasm (GTN) after the completion of chemotherapy. J Clin Oncol vol. 24, (18_suppl)

Kümmel S, Eggemann H, Lüftner D, Thomas A, Jeschke S, Zerfel N, Heilmann V, Emons G et al. (2006). Changes in the circulating plasma levels of VEGF and VEGF-D after adjuvant chemotherapy in patients with breast cancer and 1 to 3 positive lymph nodes. Anticancer Research. vol. 26, 1719-1726.

Kümmel S, Elling D, Jeschke S, Schmid P, Thomas A (2006). Chemotherapy treatment options for elderly women with breast cancer. Anticancer Research. vol. 26, 1673-1676.

Schmid P, Schippinger W, Nitsch T, Huebner G, Heilmann V, Schultze W, Hausmaninger H, Wischnewsky M et al.(2005). Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: Results of a randomized trial. Journal of Clinical Oncology vol. 23, (3) 432-440.

Schmid P, Krocker J, Jehn C, Michniewicz K, Lehenbauer-Dehm S, Eggemann H, Heilmann V, Kümmel S et al.(2005). Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: Final results of a phase II trial. Annals of Oncology vol. 16, (10) 1624-1631.

Schmid P, Heilmann V, Schulz CO, Dieing A, Lehenbauer-Dehm S, Jehn C, Sezer O, Possinger K et al.(2005). Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: A phase II study. Journal of Cancer Research and Clinical Oncology vol. 131, (9) 568-574.

Schmid P, Flath B, Akrivakis K, Heilmann V, Mergenthaler HG, Sezer O, Kreienberg R, Possinger K(2005). Gemcitabine and mitoxantrone in metastatic breast cancer: A phase-I-study. Investigational New Drugs vol. 23, (4) 349-356.

Schmid P, Possinger K(2005). Gemcitabin (Gemzar). Gynakologische Praxis vol. 29, (2) 351-358.

Schmid P, Possinger K(2005). Gemcitabine (Gemzar). Internistische Praxis vol. 45, (2) 415-422.

Schmid P, Possinger K(2005). Gemcitabin (Gemzar). Padiatrische Praxis vol. 66, (3) 521-528.

Zavrski I, Jakob C, Schmid P, Krebbel H, Kaiser M, Fleissner C, Rosche M, Possinger K et al.(2005). Proteasome: An emerging target for cancer therapy. Anti-Cancer Drugs vol. 16, (5) 475-481.

Schmid P, Possinger K(2005). Gemcitabin (Gemzar). Chirurgische Praxis vol. 64, (2) 351-358.

Schmid P, Schweigert M, Beinert T, Flath B, Sezer O, Possinger K(2005). Prolonged infusion of gemcitabine in advanced solid tumors: A phase-I-study. Investigational New Drugs vol. 23, (2) 139-146.

Schmid P, Krocker J, Schulz CO, Michniewicz K, Dieing A, Eggemann H, Heilmann V, Blohmer JU et al.(2005). Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: Results of a phase I trial. Anti-Cancer Drugs vol. 16, (1) 21-29.

Pokan R, Von Duvillard SP, Ludwig J, Rohrer A, Hofmann P, Wonisch M, Smekal G, Schmid P et al.(2004). Effect of high-volume and -intensity endurance training in heart transplant recipients. Medicine and Science in Sports and Exercise vol. 36, (12) 2011-2016.

Untch M, Kahlert S, Kosse V, Bondar G, Kienle E, Maubach L, Hillger H, Schmid P et al.(2004). Leuprorelinacetate as a 3 month depot has the same efficacy as CMF in the adjuvant therapy of pre-perimenopausal, node positive breast cancer patients with positive receptor status - The TABLE study. Geburtshilfe und Frauenheilkunde vol. 64, (12) 1316-1323.

Dieing A, Schulz CO, Schmid P, Roever AC, Lehenbauer-Dehm S, Jehn C, Flath B, Possinger K(2004). Orbital metastases in breast cancer: Report of two cases and review of the literature. Journal of Cancer Research and Clinical Oncology vol. 130, (12) 745-748.

Schmid P, Helmreich G, Gradauer L, Stowasser G, Bronnenmayer J, Pokan R(2004). Are there non responders to exercise therapy after myocardial infarction?. Journal fur Kardiologie vol. 11, (11) 453-457.

Pokan R, Hofmann P, Wonisch M, Smekal G, Bachl N, Mayr K, Benzer W, Schmid P(2004). Performance diagnostic and target training heart rate in cardiac rehabilitation. Journal fur Kardiologie vol. 11, (11) 446-452.

Höfer S, Benzer W, Brandt D, Laimer H, Schmid P, Bernardo A, Oldridge NB(2004). MacNew Heart Disease Questionnaire after myocardial infarction: The German version. Zeitschrift fur Klinische Psychologie und Psychotherapie vol. 33, (4) 270-280.

Schmid P, Krocker J, Morack G, Heilmann V, Blohmer JU, Michniewicz K, Köhler G, Schaller-Kranz T et al.(2004). Primary chemotherapy with doxorubicin and paclitaxel in patients with early breast cancer: Final results of a multicenter phase II study. Journal of Cancer Research and Clinical Oncology vol. 130, (11) 657-663.

Schmid P, Helmreich G, Gradauer L, Schmid F(2004). Percutaneous transradial artery approach for coronary diagnostics and PCI. Journal fur Kardiologie vol. 11, (9) 359-362.

Pokan R, Wonisch M, Schmid P(2004). Changes in the athlete's heart in the ECG. Internistische Praxis vol. 44, (1) 79-88.

Schmid P, Schmid F, Smekal G, Pokan R(2003). Physical Activity and Primary Prevention. Journal fur Kardiologie vol. 10, (12) 548-553.

Beslija S, Bonneterre J, Burstein HJ, Gnant M, Goodwin P, Heinemann V, Jassem J, Köstler W et al. (2003). Consensus on medical treatment of metastatic breast cancer. Breast Cancer Research and Treatment. vol. 81,

Lüftner D, Jung A, Schmid P, Geppert R, Kienle E, Wernecke KD, Possinger K(2003). Upregulation of HER-2/neu by ovarian ablation: Results of a randomized trial comparing leuprorelin to CMF as adjuvant therapy in node-positive breast cancer patients. Breast Cancer Research and Treatment vol. 80, (3) 245-255.

Langelotz C, Schmid P, Jakob C, Heider U, Wernecke KD, Possinger K, Sezer O(2003). Expression of high-mobility-group-protein HMGI-C mRNA in the peripheral blood is an independent poor prognostic indicator for survival in metastatic breast cancer. British Journal of Cancer vol. 88, (9) 1406-1410.

Schobersberger W, Schmid P, Lechleitner M, von Duvillard SP, Hörtnagl H, Gunga HC, Klingler A, Fries D et al.(2003). Austrian Moderate Altitude Study 2000 (AMAS 2000). The effects of moderate altitude (1,700 m) on cardiovascular and metabolic variables in patients with metabolic syndrome. European Journal of Applied Physiology vol. 88, (6) 506-514.

Schmid P, Possinger K (2003). Bisphosphonates in metastatic breast cancer. Breast Cancer Research and Treatment. vol. 81,

Schmid P, Possinger K (2003). Which treatment when?. Breast Cancer Research and Treatment. vol. 81,

Schmid P, Possinger K(2002). Interactions of antioestrogens and aromatase inhibitors. FORUM - Trends in Experimental and Clinical Medicine vol. 12, (1) 45-59.

Schmid P, Wischnewsky MB, Sezer O, Böhm R, Possinger K(2002). Prediction of response to hormonal treatment in metastatic breast cancer. Oncology vol. 63, (4) 309-316.

Schmid P, Possinger K(2002). High-dose chemotherapy in breast cancer. Medizinische Klinik vol. 97, (11) 677-686.

Eucker J, Schille C, Schmid P, Jakob C, Schetelig J, Kingreen D, Mergenthaler HG, Huhn D et al.(2002). The combination of fludarabine and cyclophosphamide results in a high remission rate with moderate toxicity in low-grade non-Hodgkin's lymphomas. Anti-Cancer Drugs vol. 13, (9) 907-913.

Schmid P, Untch M, Wallwiener D, Kossé V, Bondar G, Vassiljev L, Tarutinov V, Kienle E et al.(2002). Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: Preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate). Anticancer Research vol. 22, (4) 2325-2332.

Schmid P, Possinger K(2002). High-dose chemotherapy in high-risk primary breast cancer. Onkologie vol. 25, (2) 112-120.

Schmid P, Possinger K(2002). Systemic therapy in breast cancer - Adjuvant and neo-adjuvant treatment: Update situation and update studies. Viszeralchirurgie vol. 37, (2) 137-149.

Schmid P, Possinger K(2002). Adjuvant and neoadjuvant systemic therapy of breast cancer. Internist vol. 43, (3) 341-353.

Pokan R, Hofmann P, Smekal G, Wonisch M, Bachl N, Schmid P(2002). Performance testing for regulating training in exercise therapy of cardiovascular disease. Internistische Praxis vol. 42, (4) 797-806.

Schmid P, Sezer O, Possinger K(2001). Bisphosphonates in oncology. Pharmazie in Unserer Zeit vol. 30, (6) 519-528.

Schmid P, Fritz J, Possinger K(2001). Treatment options for metastatic breast cancer. Internistische Praxis vol. 41, (2) 319-332.

Sezer O, Eucker J, Jakob C, Kaufmann O, Schmid P, Possinger K(2001). Achievement of complete remission in refractory Hodgkin's disease with prolonged infussion of gemcitabine. Investigational New Drugs vol. 19, (1) 101-104.

Sinzinger H, Hoppichler F, Kritz H, Laimer H, Schmid P, Silberbauer K, Toplak H(2001). HDL-2000 - Ein konsensus. Wiener Klinische Wochenschrift vol. 113, (5-6) 212-214.

Grosse Y, Schmid P, Possinger K(2001). Bisphosphonates in the treatment of breast cancer. Prevention and adjuvant therapy. Tagliche Praxis vol. 42, (4) 727-734.

Pokan R, Pelikan J, Retzer H, Hofmann P, Von Duvillard SP, Smekal G, Wonisch M, Fruhwald FM et al.(2001). Leistungsfähigkeit und herzfrequenz von patienten mit KHK im MAXLASS und deren zusammenhang mit dem herzfrequenzverhalten und der myokardialen funktion unter belastung im stufentest. Deutsche Zeitschrift fur Sportmedizin vol. 52, (7-8)

Schmid P, Possinger K(2001). Liposomal anthracyclines for improved cardiac tolerability. Breast vol. 10, (SUPPL. 2) 22-27.

Schmid P(2001). Stellenwert der Bewegungstherapie in der Primär- und Sekundärprävention der KHK. Deutsche Zeitschrift fur Sportmedizin vol. 52, (7-8)

Lueftner DI, Schmid P, Kienle E, Possinger K(2001). Upregulation of Her-2/neu under chemical castration: Serum results of a randomized trial comparing leuprorelin acetate to CMF for adjuvant therapy of nodal-positive breast cancer. Breast Cancer Research and Treatment vol. 69, (3)

Sezer O, Eucker J, Jakob C, Schmid P, Possinger K(2000). Prolonged infusion of gemcitabine in refractory hodgkin's disease. Blood vol. 96, (11 PART II)

Possinger K, Schmid P (2000). Therapeutic possibilities in breast carcinoma. Onkologe. vol. 6,

Sezer O, Langelotz C, Blohmer JU, Schmid P, Akrivakis K, Possinger K(2000). Detection of HMGI-C in the peripheral blood of breast cancer patients. European Journal of Cancer vol. 36, (15) 1944-1948.

Schmid PE, Tokeshi M, Schmid-Araya JM(2000). Relation between population density and body size in stream communities. Science vol. 289, (5484) 1557-1560.

Schmid P, Possinger K(2000). Advanced breast cancer. Palliative measures are becoming ever more tolerable. MMW-Fortschritte der Medizin vol. 142, (35) 22-24.

Possinger K, Schmid P(2000). New drugs for the treatment of breast cancer. Onkologe vol. 6, (5) 392-409.

Böttner A, Pirro F, Schmid P, Traeder W, Weiskopf S, Weiss H, Zschiesche E(2000). [Guidelines for planning studies to determine the resistance of infectious agents of veterinary relevance]. Berl Munch Tierarztl Wochenschr vol. 113, (7-8) 299-305.

Sinzinger H, Chehne F, Schmid P, Kritz H(2000). Plasma homocysteine is not altered during simvastatin-therapy. Wiener Klinische Wochenschrift vol. 112, (12) 540-543.

Pokan R, Von Duvillard SP, Hofmann P, Smekal G, Fruhwald FM, Gasser R, Tschan H, Baron R et al.(2000). Change in left atrial and ventricular dimensions during and immediately after exercise. Medicine and Science in Sports and Exercise vol. 32, (10) 1713-1718.

Beinert T, Binder D, Oehm C, Ziemer S, Priem F, Stuschke M, Schweigert M, Siebert G et al.(2000). Further evidence for oxidant-induced vascular endothelial growth factor up-regulation in the bronchoalveolar lavage fluid of lung cancer patients undergoing radio-chemotherapy. Journal of Cancer Research and Clinical Oncology vol. 126, (6) 352-356.

Sezer O, Eucker J, Schmid P, Possinger K(2000). New therapeutic approaches in primary systemic AL amyloidosis. Annals of Hematology vol. 79, (1) 1-6.

Sezer O, Schmid P, Hallek M, Schweigert M, Beinert T, Langelotz C, Mergenthaler HG, Possinger K(1999). Eosinophila during fludarabine treatment of chronic lymphocytic leukemia. Annals of Hematology vol. 78, (10) 475-477.

Sinzinger H, Schmid P, O'Grady J(1999). Two different types of exercise-induced muscle pain without myopathy and CK-elevation during HMG-Co-enzyme-A-reductase inhibitor treatment [3]. Atherosclerosis vol. 143, (2) 459-460.

Helmreich G, Gradauer L, Schmid P(1999). Duration and complications in diagnostic coronary angiography via the radial artery. Journal fur Kardiologie vol. 6, (10-11) 545-549.

Schmid P, Helmreich G, Gradauer L(1999). Methods for diagnostic coronary angiography via the radial artery. Journal fur Kardiologie vol. 6, (10-11) 538-542.

Schmid P, Akrivakis K, Flath B, Grosse Y, Sezer O, Mergenthaler HG, Possinger K(1999). Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. Anti-Cancer Drugs vol. 10, (7) 625-631.

Akrivakis K, Schmid P, Flath B, Schweigert M, Sezer O, Mergenthaler HG, Possinger K(1999). Prolonged infusion of gemcitabine in stage IV breast cancer: A phase I study. Anti-Cancer Drugs vol. 10, (6) 525-531.

Sezer O, Schmid P, Schweigert M, Heider U, Eucker J, Harder H, Sinha P, Radtke H et al.(1999). Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support. Bone Marrow Transplantation vol. 23, (9) 967-969.

Pokan R, Hofmann P, Von Duvillard SP, Smekal G, Hogler R, Tschan H, Baron R, Schmid P et al.(1999). The heart rate turn point reliability and methodological aspects. Medicine and Science in Sports and Exercise vol. 31, (6) 903-907.

Sezer O, Schmid P, Mergenthaler HG, Beinert T, Possinger K(1999). Use of bisphosphonates in therapy and prophylaxis of cancer-induced bone diseases. Onkologie vol. 22, (5) 400-404.

Pokan R, Hofmann P, Von Duvillard SP, Beaufort F, Smekal G, Gasser R, Klein W, Eber B et al.(1998). The heart rate performance curve and left ventricular function during exercise in patients after myocardial infarction. Medicine and Science in Sports and Exercise vol. 30, (10) 1475-1480.

Pokan R, Hofmann P, Von Duvillard SP, Schumacher M, Gasser R, Zweiker R, Fruhwald FM, Eber B et al.(1998). Parasympathetic receptor blockade and the heart rate performance curve. Medicine and Science in Sports and Exercise vol. 30, (2) 229-233.

Hofmann P, Pokan R, Von Duvillard SP, Schmid P, Conconi F, Grazzi G, Casoni I, Borsetto C et al.(1997). The Conconi test (multiple letters) [2]. International Journal of Sports Medicine vol. 18, (5) 397-399.

Pokan R, Hofmann P, Von Duvillard SP, Beaufort F, Schumacher M, Fruhwald FM, Zweiker R, Eber B et al.(1997). Left ventricular function in response to the transition from aerobic to anaerobic metabolism. Medicine and Science in Sports and Exercise vol. 29, (8) 1040-1047.

Hofmann P, Pokan R, Bachl N, Schmid P(1997). A short communication regarding the article by M. Kara et al. "Determination of the heart rate deflection point by the Dmax method." (J Sports Med Phys Fitness 1996;36(1):31-4). The Journal of sports medicine and physical fitness vol. 37, (2) 151-155.

O'Grady J, Kritz H, Schmid P, Pirich C, Sinzinger H(1997). Effect of isradipine on in-vivo platelet function. Thrombosis Research vol. 86, (5) 363-371.

Hofmann P, Pokan R, Von Duvillard SP, Seibert FJ, Zweiker R, Schmid P(1997). Heart rate performance curve during incremental cycle ergometer exercise in healthy young male subjects. Medicine and Science in Sports and Exercise vol. 29, (6) 762-768.

Kritz H, Schmid P, Karanikas G, Rodrigues M, Sinzinger H(1997). Detection of early atherosclerotic lesions in the carotid artery: Experimental and preliminary human data. International Journal of Angiology vol. 6, (1) 24-29.

Kritz H, Schmid P, Karanikas G, Pirich C, Stamatopoulos Y, Peskar BA, Sinzinger H(1996). Passive smoking increases platelet thromboxane. International Journal of Angiology vol. 5, (3) 134-139.

Hentrich MU, Brack NG, Schmid P, Schuster T, Clemm C, Hartenstein RC(1996). Testicular germ cell tumors in patients with human immunodeficiency virus infection. Cancer vol. 77, (10) 2109-2116.

Benzer W, Schmid P, Maehr G, Drexel H(1996). Effects of intravenous magnesium chloride reverses left ventricular end-diastolic pressure in coronary artery disease. American Journal of Cardiology vol. 77, (8) 638-640.

Schmid P, Karanikas G, Kritz H, Pirich C, Stamatopoulos Y, Peskar BA, Sinzinger H(1996). Passive smoking and platelet thromboxane. Thrombosis Research vol. 81, (4) 451-460.

Otto F, Schmid P, Mackensen A, Wehr U, Seiz A, Braun M, Galanos C, Mertelsmann R et al.(1996). Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer. European Journal of Cancer Part A vol. 32, (10) 1712-1718.

Sinzinger H, Kritz H, Virgolini I, Schmid P, Rogatti W(1996). Prostaglandin E<inf>1</inf> increases binding of¹²³l-low-density lipoprotein to the human liver in vivo. European Journal of Clinical Pharmacology vol. 49, (6) 515-520.

Kritz H, Schmid P, Keiler A, O'Grady J, Sinzinger H(1995). Isradipine increases vascular prostaglandin I<inf>2</inf>-formation while the thromboxane B<inf>2</inf>-synthesis is diminished. Thrombosis Research vol. 80, (6) 483-489.

Benzer W, Schmid P(1995). Rehabilitation after myocardial infarct--a multidisciplinary responsibility. Wiener klinische Wochenschrift vol. 107, (24)

Kritz H, Schmid P, Sinzinger H(1995). Passive Smoking and Cardiovascular Risk. Archives of Internal Medicine vol. 155, (18) 1942-1948.

Pokan R, Hofmann P, Lehmann M, Leitner H, Eber B, Gasser R, Schwaberger G, Schmid P et al.(1995). Heart rate deflection related to lactate performance curve and plasma catecholamine response during incremental cycle ergometer exercise. European Journal of Applied Physiology and Occupational Physiology vol. 70, (2) 175-179.

Sinzinger H, Mayr F, Schmid P, Granegger S, O'Grady J, Peskar BA(1994). Sleep disturbance and appetite loss after lovastatin. The Lancet vol. 343, (8903)

Pirich C, Schmid P, Fitscha P, Wytek R, O'Grady J, Sinzinger H (1994). Influence of calcium antagonists on platelet function and vascular prostacyclin production. Blood Pressure, Supplement. vol. 3, 75-80.

Pirich C, Fitscha P, Schmid P, Sinzinger H (1994). Isradipine decreases the entry of radioiodine-labelled low-density lipoproteins into the arterial wall. Blood Pressure, Supplement. vol. 3, 70-74.

Schmid P, Pirich C, Fitscha P, Pesau B, Virgolini I, Sinzinger H (1994). Isradipine increases platelet - Low-density lipoprotein binding: Evidence from ex-vivo studies in humans. Blood Pressure, Supplement. vol. 3, 65-69.

Sinzinger H, Schmid P, Pirich C, Virgolini I, Pesau B, Granegger S, O'Grady J(1992). Treatment of hypercholesterolaemia in children. The Lancet vol. 340, (8818) 548-549.

Pirich C, Schmid P, Pidlich J, Sinzinger H(1992). Cholesterol lowering by Anticholest® - a high-fiber guar-pectin drink. Wiener Klinische Wochenschrift vol. 104, (11) 314-316.